Date  |
|
| Mar 29, 2019 |
CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study |
| Mar 25, 2019 |
CEL-SCI Corporation Releases Letter to Shareholders |
| Mar 7, 2019 |
CEL-SCI Selected by National Institutes of Health to Showcase Its LEAPS Technology at BIO International Convention |
| Mar 4, 2019 |
CEL-SCI’s Scientific Article on Vaccines for Autoimmune Disease Published in Journal of Clinical & Cellular Immunology |
| Feb 14, 2019 |
CEL-SCI Corporation Reports First Quarter Fiscal 2019 Financial Results |
| Feb 7, 2019 |
CEL-SCI to Present at 2019 BIO CEO & Investor Conference |
| Jan 23, 2019 |
U.S. Patent Office Issues CEL-SCI Two Patents for Its LEAPS Vaccine Platform Technology |
| Jan 15, 2019 |
CEL-SCI Regains Full Listing Compliance with NYSE American |
| Dec 20, 2018 |
CEL-SCI Reports Fiscal 2018 Financial Results and Clinical & Corporate Developments |
| Oct 23, 2018 |
CEL-SCI Receives about $8 Million from Warrant Exercises |